nasal epinephrine use: caution advised with nasal drugs, including subsequent nasal epinephrine doses, up to 2 wk after initial administration; nasal epinephrine may incr. systemic absorption of nasal drugs, risk of adverse effects

avoid combo of lamivudine oral solution with oral products containing sorbitol; may give lamivudine tab formulation or monitor virologic response more frequently if combo cannot be avoided; sorbitol may decr. bioavailability of lamivudine, resulting in decr. levels, efficacy